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Purpose: To develop and validate a sensitive HPLC method for the separation and simultaneous 
estimation of two ingredients in a composition comprising of rifampicin and a flavonoid glycoside (an 
enhancer of oral bioavailability of rifampicin). 
Methods: Reverse phase (RP) chromatographic separation and estimation was achieved using a 
Shimadzu HPLC system.  RP-18 column was used at the following optimised conditions: mobile phase, 
acetonitrile:phosphate buffer, 50 mM, pH 5.0 in a ratio of 60:40 v/v; oven temperature, 40 
0
C; flow rate, 
0.8 ml min
-1
; detection wavelength, 340 nm; and total run time, 15 min.  
Results: The developed method was validated in terms of linearity, range, accuracy, precision, limit of 
detection, limit of quantification, robustness and specificity. Good linearity was observed (r
2
 > 0.999) 
over the study range of both ingredients. The precision values for rifampicin and the flavonoid glycoside 
were in the range 1.08-2.77 and 1.14-2.98 %, respectively, while the limit of quantification was 0.10 and 
0.05µg mL
-1
 respectively. The method was found to be robust and specific for both ingredients. 
Conclusion: The developed method has a potential application in preclinical and clinical studies. 
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INTRODUCTION 
 
Recently, the use of natural products in 
combination with prescription drugs has 
attracted interest with regard to possible 
improvement in drug disposition profile since 
one of the major consequences of herb-drug 
interactions is altered drug bioavailability [1-
3]. Consequently, herb-drug combinations 
are increasingly being examined as a useful 
strategy to enhance drug bioavailability [4].  
 
In our earlier studies, a flavonoid glycoside 
isolated from Cuminum cyminum (cumin 
seed) and identified as 3′, 5–
dihydroxyflavone 7-O-β-D-galacturonide-4′-
O-β-D-glucopyranoside (CC-I) (Fig. 1), 
showed a pharmacokinetically meaningful  
interaction with rifampicin (RIF) , resulting in 















A significant increase in AUC (53 %) and 
Cmax (35 %) of RIF was evident when the 
drug was administered in combination with 
CC-I per orally in rats [5].  In view of the 
low/variable systemic bioavailability of orally 
administered RIF in a fixed drug combination 
[6], we intend to extend the pre-clinical 
studies of a composition consisting of RIF  
and this flavonoid glycoside (CC-I). Since 
incidences of possible drug interactions 
between concomitantly administered drugs 
are known to alter their pharmacokinetic 
profiles, we sought to develop and validate a 
RP-HPLC method for simultaneous 
estimation of both analytes (RIF and CC-I) in 
a single run.  The present report deals with 
this method development in terms of 
specificity, recovery, linearity, accuracy and 
precision, as per the guidelines of 
International Conference on Harmonisation 
of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH) [7], 
and in the shortest possible time, for quality 
assurance and routine analysis of the blend.  
Accelerated and ambient stability studies are 




Reagents and chemicals 
 
RIF was purchased from Sigma (St. Louis, 
Mo, USA). All HPLC grade solvents and 
water were procured from Rankem, Mumbai, 
India. A 97 % pure CC-I (mol. formula, 
C27H28O17; MW, 624; melting point, 270 
0
C) 
sample was prepared as described earlier [5]. 
Based upon previous animal studies [5], the 
amounts of RIF and CC-I in the composition 
were adjusted to 450 mg and 50 mg, 




The HPLC system (Shimadzu, Japan) 
consisted of a diode array detector (SPD-
M10AVP), solvent delivery module (LC-
10ATVP), online degasser (DGU-14A), an 
auto-injector (SIL-10ADVP), flow channel 
system (FCV-14AH), system controller (SCL-
10AVP), and a reversed-phase HPLC column 
(RP-18, 250 mm × 4.6 mm, 5 µm particle 
size, Sigma, USA). Data analysis was carried 
out using Class VP V6.12 SP2 software 
(Shimadzu, Japan). Stability studies were 
performed using a Climacell 222 stability 
chamber (BMT, Germany). A Cerius-2, 3D 
sketcher software was used for the 
determination of log P and hydration energy 
of CC-I. 
 
Chromatographic conditions  
 
The chromatographic elution was carried out 
in isocratic mode using a mobile phase 
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phosphate buffer (pH 5.0) in a ratio of 60:40 
v/v. The analysis was performed at 40 
0
C 
using a flow rate of 0.8 mL min
-1
 within a run 
time of 15 min. The 340 nm detection 
wavelength was found to be the same for 
both analytes.  
 
Preparation of reference solutions 
 
RIF (50 mg) was weighed accurately using a 
pre-calibrated weighing balance, transferred 
into a 50 mL volumetric flask, dissolved (by 
sonication) and diluted with acetonitrile to 
achieve 1 mg mL
-1
 strength (Stock I). CC-I 
(10 mg) was accurately weighed, transferred 
into a 10 mL volumetric flask, dissolved in 
HPLC grade water and diluted suitably to a 
final volume having a concentration of 1 mg 
mL
-1
 (Stock II). The flasks containing the 
reference solutions were covered with 
aluminium foil and sealed with paraffin film to 
avoid degradation and loss due to 
evaporation.  
 
Preparation of calibration, quality control and 
system suitability standards 
 
Stock I and II solutions were separately 
diluted serially with the mobile phase to 
obtain stock III (50 µg mL
-1
 of RIF) and stock 
IV (50 µg mL
-1
 of CC-I) solutions. Stock III 
and IV were mixed and then diluted with the 
mobile phase to obtain six calibration 
standards (0.1, 0.5, 1.0, 2.5, 5.0, and 10.0 µg 
mL
-1
), three quality control standards (0.1, 
2.5, and 10.0 µg mL
-1
); and one system 




Sample preparation from composition 
 
From three different batches of rifampicin-
flavonoid glycoside mixtures, 18 samples (6 
per batch) were selected and weighed. 
Empty shells were weighed to determine the 
average fill weight. After homogeneous 
mixing of the contents (using glass mortar 
and pestle), the quantities equivalent to 90 
mg of  RIF and 10 mg of CC-I (total weight: 
100 mg capsule contents) were transferred to 
a 100 mL volumetric flask. Following the 
addition of a small quantity of the mobile 
phase (approximately 50 mL), the contents 
were intermittently vortexed and sonicated for 
10 min to ensure complete dissolution of the 
contents (by visual inspection), and the 
volume was adjusted to mark with the mobile 
phase. The solution was mixed properly with 
shaking and filtered through a 0.45 µm pore 
filter into amber coloured glass vials. The 
filtrate was diluted suitably with the mobile 
phase to bring the concentrations of RIF and 
CC-I to fall within their respective calibration 




The method was validated in accordance with 
ICH guidelines. The parameters assessed 
were linearity, range, accuracy, precision, 





The system suitability test was performed 
using 9 replicate injections of system 
suitability standard before analysis of 
samples. The acceptance parameters of both 
RIF and CC-I were less than 0.5  and 1.5 % 
relative standard deviation (R.S.D.) for 
retention time and peak area, respectively, 
along with more than 3500 theoretical plates. 
The resolution (criterion > 3) was calculated 
using the formula: R = 1.18 [(t2-t1) / (W2 + 
W1)] ,  where t2 and t1 are the retention times 
of RIF and CC-I, respectively, and W2 and W1 
are their respective peak widths at half 
height. 
 
Linearity and range 
 
Six calibration standards (0.1-10 µg mL
-1 
for 
RIF and 0.05-10 µg mL
-1
 for CC-I in 
combination) were utilised. The peak area vs 
concentration plots were subjected to linear 
least square regression analysis. The intra- 
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Accuracy and precision 
 
Intra- and inter-day accuracy were  
established from quality control standards by 
evaluating nominal and mean measured 
concentrations of quality control standards 
which were compared and expressed as % 
difference  (diff %). Diff % was calculated 
using the formula: Diff % = [(mean measured 
concentration - nominal concentration)/ 
nominal concentration] x 100. The intra and 
inter-day accuracy were also determined for 
the composition using spiked samples.  The 
100 mg contents of the composition (90 mg 
RIF + 10 mg CC-I) were spiked with a 
suitable combination of known stock solutions 
of RIF and CC-I to achieve a total content of 
200 mg (180 mg RIF + 20 mg CC-I). The 
spiked contents were dissolved and the 
volume made up to 200 mL with mobile 
phase. The solution was then diluted serially 
with the mobile phase to achieve 3 solutions: 
solution A (0.90 mg RIF + 0.10 mg CC-I), 
solution B (1.80 mg RIF and 0.20 mg CC-I) 
and solution C (4.50 mg RIF + 0.50 mg CC-I). 
The intra- and inter-day precision (% RSD) - 
for both RIF as well CC-I - were established 
by analysing 9 replicates each of 3 quality 
control standards on day 1 and again on 
each of three consecutive days.  
 
Limit of quantitation (LOQ) 
 
The lowest concentration of calibration curve 
with acceptable accuracy and precision (% 





The robustness of the method was evaluated 
by analysing quality control standards after 
multiple ratio adjustments in the mobile 
phase composition and pH of the aqueous 
buffer. The acetonitrile volume in the mobile 
phase was modified to between 55 and 65 %. 
The pH range selected for study was from 4.5 
to 5.5. The acceptance criteria were less than 
2 % variation in the final results after 




The stability indicating criteria and specificity 
of the method were determined by using a 
mixture of stock I (reference solution of RIF) 
and stock II (reference solution of CC-I) in 1:1 
(v/v) ratio (stock V). Stock V solution was 
divided into two parts: one part was stored at 
room temperature in the presence of light 
while the other part was stored protected 
from light. The analysis was performed on 
days 1, 3 and 6 after storage. The stability 
criteria were less than 2 % change in 
concentration after the specified storage. To 
ensure specificity of the method, stock V 
(containing both RIF and CC-I) was stressed 
under individual conditions for 24 h in: 1.0 N 
HCl, 1.0 N NaOH, 30% w/v H2O2, and 50 mM 
Tris buffer pH 8.0. After 24 h, samples were 
analysed for RIF and CC-I. The peak purity 
was considered as a parameter and 
evaluated using photo-diode array detector 
and peak purity software. The upslope, apex 
and downslope portions of the peak were 
compared by superimposing the respective 
chromatograms. The peak was considered 
pure only when identical spectra were found 




The following HPLC conditions showed best 
resolution of RIF and CC-I in terms of  
retention time, peak characteristics and total 
run time: (a) mobile phase - acetonitrile : 
KH2PO4 buffer (pH 5, 50 mM)  60:40 (v/v); (b) 
flow rate - 0.8 mL min
-1
; (c) column head 
pressure – 808 - 838 psi; (d) column - RP-18  
(250 x 4.6 mm, 5 µm); and (e) column oven 
temperature, 40 
0
C. The respective retention 
time of RIF and CC-I was 4.779 and 3.072 
min under the above HPLC conditions. 
 
System suitability test showed that critical 
parameters such as retention time, area and 
number of theoretical plates met the 
acceptance criteria on all the experimental 
days (Table 1).  
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Parameter   Acceptance Average Low High %RSD Status 
RIF Retention time       % RSD < 0.5    4.773 4.768 4.779 0.122 Passed 
 Peak area           % RSD < 1.5    333036 3283  337270 0.894 Passed 
 No. of Plates  > 3500      4025.08      3978.01   4052.47   0.717 Passed 
CC-I Retention time      % RSD < 0.5     3.070 3.061 3.072 0.142 Passed 
 Peak area               % RSD < 1.5     328056 326444 331202 0.537      Passed 
 No. of Plates > 3500 5142.50 5086.68 5182.68   1.480      Passed 
 
 
Adequate resolution of > 6 between RIF and 
CC-I peaks was observed. The linearity and 
range of calibration curves were assessed by 
constructing standard curves for RIF (0.10-
10.00 µg mL
-1
) and CC-I (0.05-10.00 µg mL
-
1
). Analysis of three independent sets 
showed good correlation between 
concentration and resulting peak area for 
both analytes (RIF: slope, 0.48, y-intercept, 
2.26, and r
2
, >0.999; CC-I: slope, 0.00046, y-
intercept, 0.24351, and r
2
, >0.999). The 
accuracy and precision were established by 
using 9 replicates each of 3 different quality 
control standards. The intra- and inter-day 
accuracy (diff. %) for RIF was in the range of  
−3.34 to +3.28 and −4.87 to +2.88 
respectively, while for CC-I, it was from −4.59 
to +3.42 and −3.62 to +3.50, respectively. 
The intra- and inter-day precision (% RSD) 
for RIF was in the range of 1.08 to 2.61 and 
1.62 to 2.77, respectively, while for CC-I, it 
was 1.22 to 2.66 and 1.14 to 2.98, 
respectively. RIF + CC-I mixture was 
subjected to batch-wise accuracy 
measurement after spiking 50 % of the 
known amounts of analytes. The intra- and 
inter-day accuracy (diff. %) of RIF was 
−2.932 to +2.78 and −3.92 to +2.17, 
respectively, and for CC-I, it was −3.61 to 
+3.60, and −5.01 to +2.34, respectively. 
Based on the acceptable accuracy and 
precision, the LOQ of RIF and CC-I were 
0.10 and 0.05 µg mL
-1
, respectively. 
Minor modifications of mobile phase 
composition and pH of buffer did not 
significantly alter the performance of the 
method in terms of retention time, resolution, 
peak characteristics and theoretical plates. 
CC-I solution was stable at all the storage 
conditions for at least 6 days. The reference 
solution of RIF, after storage at room 
temperature for 24 h in the presence of light, 
showed 9.5 % degradation (established on 
the basis of peak purity). 
The stability studies were performed at 
ambient and accelerated conditions (in 
compliance with regulatory requirements) of 
25 ± 2 
0
C and 60 ± 5 % RH, and 40 ± 2 
0
C 
and 75 ± 5 % RH, respectively. The results 
showed a reduction of RIF content from 
100.2 to 92.2 % and followed first order 
kinetics (Fig 2A). CC-I content declined from 
102.8 to 98.5 % (Fig 2B).  
 
 
Fig. 2A: Accelerated stability study of rifampicin at 
40±2 
0
C and 75±5 % RH 
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Fig. 2B: Accelerated stability study of CC-I at 
40±2 
0
C and 75±5 % RH.  
 
A 12 month study showed the average shelf 
life of 22.89 months (on the basis of RIF). 
 
Fig. 2C: Stability of rifampicin at ambient 
conditions (25 ±2 
0
C and 60 ±5 % RH) 
 
 
Fig. 2D: Stability of CC-I at ambient 
conditions (25±2 
0




CC-I, a flavonoid glycoside, is a highly polar 
compound. It is expected to be poorly 
retained on reverse phase HPLC column, 
hence the smaller retention time. RIF, on the 
other hand, is relatively non-polar and 
showed stronger retention. Simultaneous 
analysis of the two analytes, which are 
chemically different, in a single run under 
similar chromatographic conditions was a 
difficult task. Ensuring the quality of the 
composition in terms of RIF and CC-I assay 
and minimising the analysis time for the 
assays were the main objectives of the study. 
Therefore, a method has been developed for 
the analysis of both ingredients in a mixture 
simultaneously under similar 
chromatographic conditions and in the 
shortest possible time. The method 
development involved optimisation of the 
buffer - its strength and pH. Several 
stationary and mobile phases were tried. A 
range of columns of different materials were 
tested, along with different mobile phase 
compositions. In preliminary studies, various 
buffers from lower to medium strength were 
combined with methanol or acetonitrile (data 
not shown). Finally, method parameters such 
as mobile phase composition, its pH, flow 
rate, etc, were optimised on the basis of peak 
characteristics and run time.  
 
The method was validated for its 
performance in terms of linearity, range, 
accuracy, precision, LOQ, robustness and 
specificity for both RIF as well as CC-I. The 
ICH guidelines were followed for validating 
the method. To ensure the validity of a 
system and an analytical method, system 
suitability test was performed. Adequate 
resolution between RIF and CC-I peaks 
showed the efficiency of the method to 
identify and quantify each analyte at the 
same time with no interference. The method 
was found to be robust as minor intentional 
changes in the method parameters did not 
alter method performance. Based on the 
stability data of RIF solution, a fresh RIF 
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solution needs to be prepared each time 
before analysis. 
 
The validated method was utilized 
successfully for determining the stability of 




In the present investigation, a simple, 
accurate, precise and robust RP-HPLC 
method has been developed for the 
determination of both ingredients (RIF and 
CC-I) in a composition. The method has 
potential application in quality evaluation and 
prospective clinical investigations.    
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